Nevirapine Mylan

Nevirapine, the active ingredient in Nevirapine Mylan, is a non‑nucleoside reverse transcriptase inhibitor (NNRTI) presented as an oral tablet for oral use. It is employed in the treatment of HIV‑1 infection as part of combination antiretroviral therapy for adults and children. It is indicated for patients with confirmed HIV‑1 infection who need a potent antiviral within a multi‑drug regimen.

GNH USA supplies Nevirapine Mylan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality‑assured manufacturing and distribution networks that meet European Union standards.

Nevirapine is used in antiretroviral therapy to suppress HIV‑1 replication.

- HIV‑1 infection (adults): Used as part of combination therapy to achieve sustained viral load reduction. - HIV‑1 infection (children): Provides an effective antiviral component within pediatric antiretroviral regimens. - Treatment‑experienced patients: Added to regimens when resistance to other agents is present. - Prevention of mother‑to‑child transmission: Included in maternal regimens to reduce vertical transmission risk.

Nevirapine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Rash: mild to moderate skin eruptions. - Nausea: occasional gastrointestinal upset. - Fatigue: general tiredness. - Headache: transient cranial discomfort. - Abdominal pain: mild stomach discomfort. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Stevens‑Johnson syndrome: severe skin reaction requiring immediate medical attention. - Hepatic failure: signs of liver toxicity such as jaundice. - Severe hypersensitivity: systemic allergic response. - Hepatotoxicity: elevated liver enzymes. - Severe neutropenia: marked reduction in white blood cells. - Life‑threatening rash: extensive skin involvement.

Nevirapine requires careful monitoring and patient counseling to minimize risks.

- Liver function monitoring: check transaminases before initiation and regularly thereafter. - Rash surveillance: discontinue immediately if severe or progressing. - Hypersensitivity awareness: educate patients about signs of systemic allergic reactions. - Pregnancy considerations: assess risk‑benefit ratio before use in pregnant women. - Hepatic impairment dosing: adjust or avoid in patients with moderate to severe liver disease. - Drug interaction review: evaluate concomitant medications that affect CYP3A4. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Nevirapine interacts with several agents that can alter its efficacy or safety.

Major Interactions (Avoid): - Rifampicin: induces metabolism, reducing nevirapine levels. - St. John’s wort: strong CYP3A4 inducer, may lower drug exposure. - Protease inhibitors (e.g., ritonavir): can increase nevirapine concentrations, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Efavirenz: may increase hepatic toxicity when combined. - Zidovudine: requires monitoring for additive hematologic effects. - Hormonal contraceptives: nevirapine may reduce contraceptive efficacy. - Certain anticonvulsants (e.g., carbamazepine): may modestly decrease nevirapine levels. - Antifungal azoles (e.g., ketoconazole): can increase nevirapine exposure.